Form 4: Gilead Sciences CFO Exercises Stock Options and Sells Shares Under 10b5-1 Plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, executed stock options and sold a portion of the acquired shares on January 31, 2025, under a pre-arranged trading plan.

Summary

• Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, exercised non-qualified stock options to acquire 142,180 shares of common stock on January 31, 2025.
• These options were exercised at prices of $57.92, $72.34, and $65.38 per share.
• Following the exercise of these options, Mr. Dickinson sold 142,180 shares of common stock at a price of $97.22 per share.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.
• After these transactions, Mr. Dickinson directly owns 129,873 shares of Gilead Sciences common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing for insider transactions, which is neither positive nor negative. It reflects standard executive compensation practices.

Industry Context

This is a routine filing for insider transactions and is common for executives who receive stock options as part of their compensation. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical and biotechnology sectors like Amgen (AMGN) and Regeneron (REGN).
• These plans allow insiders to sell shares without concerns about insider trading violations.
• The vesting schedule of the options, with 25% vesting on the first anniversary and the remainder vesting quarterly, is a typical structure for stock options in the industry.
• The exercise prices of the options are typical for grants made in prior years, and the sale price reflects the current market value of the stock.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-planned trading strategy.
• The sale of shares by the CFO may slightly increase the supply of shares in the market, but the impact is likely to be negligible.

Key Dates

Keywords

Gilead Sciences, Stock Options, Rule 10b5-1, Insider Trading, Andrew D. Dickinson, CFO, Share Sale, Equity